Here is the design of a clinical trial:

Official Title: The Procalcitonin Guided Antibiotics in Respiratory Infections in General Practice

Included conditions:
- Acute Respiratory Tract Infection

Study Armgroups:
- {'label': 'Procalcitonin in addition to usual care', 'type': 'EXPERIMENTAL', 'description': 'Procalcitonin values will be disclosed to the attending physician and assist in antibiotic guidance in addition to usual care', 'interventionNames': ['Diagnostic Test: Procalcitonin']}
- {'label': 'Usual care', 'type': 'NO_INTERVENTION', 'description': 'Usual best standard care. No procalcitonin values disclosed to attending physician .'}

Interventions:
- {'type': 'DIAGNOSTIC_TEST', 'name': 'Procalcitonin', 'description': 'In addition to usual care diagnostic and handling of acute respiratory tract infections in general practice to attending physician in the intervention arm has access to antibiotic stewardship by a procalcitonin point-of-care test. The following criteria for initiating og withholding antibiotics will be used.\n\n* Antibiotics treatment is recommended with Procalcitonin levels above 0.25 ng/ml\n* Antibiotic treatment is discouraged if Procalcitonin levels are below 0.25 ng/ml', 'armGroupLabels': ['Procalcitonin in addition to usual care']}

Primary Outcomes:
- {'measure': 'Duration of illness and symptoms from acute respiratory tract infections.', 'description': "The patient reported primary outcome will be assessed as number of days to a patient's daily activities (work or recreation) are no longer restricted by symptoms from a respiratory tract infection.The non-inferiority margin between the intervention and control group is set at a one day difference. The recovery measure will be the specific day indicated by the participants using the validated Acute Respiratory Tract Infections Questionaire (ARTIQ).", 'timeFrame': 'up to 14 days'}

Please estimate the sample size based on the assumption: 
The power is set at 85% and the significance level (α) at 0.025. The study also assumes a 10% dropout rate.
Sample size
          A comparable study by Briel et al. [18] showed that the number of days when patients experienced restrictions from an ARTI had a standard deviation of 4 days. The PARI projectâs non-inferiority design allows for a clinical non-important difference in sickness of max. 1Â day in the PCT group compared to the standard care group. We expect an ARTI to last on average 9 days [21, 22]. The power (1-Î²) is set at 85% and Î± at 0.025 (non-inferiority study design). We believe these are relevant estimates since non-inferiority of a PCT-guided antibiotic treatment has previously been demonstrated [18, 19].
          The two arms of the study will be randomized 1:1 with 231 participants in each arm. We estimate that 10% of participants will not complete the project, so a total of 508 participants will be needed.